PIKTOR's Phase 2 endometrial readout will determine whether a 71% Phase 1b response rate in PI3K-mutant tumors translates to registrational-quality evidence

Bull

A positive outcome would be a response rate and durability profile that confirms the Phase 1b signal across a larger, protocol-specified PI3K-mutant endometrial population, ideally with complete responses and a progression-free survival benefit that clears a pre-specified bar. This would validate PIKTOR as a potential registrational-grade asset, support an accelerated approval filing, and substantially de-risk the breast cancer expansion program given shared mechanistic logic.

Bear

The most likely failure modes are a response rate that regresses meaningfully from the 71% Phase 1b figure — due to small Phase 1b sample size, patient selection differences, or regression to the mean — or responses that prove shallow and short-lived, undermining durability. Toxicity from the serabelisib-sapanisertib combination, including hyperglycemia and mucositis typical of dual PI3K/mTOR blockade, could also force dose reductions that compromise efficacy in the broader Phase 2 population.